301 Binney Street
3rd Floor
Cambridge, MA 02142
United States
857 259 3860
https://scholarrock.com
Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 150
Name | Title | Pay | Exercised | Year Born |
---|---|---|---|---|
Dr. Jay Thomas Backstrom M.D., M.P.H. | President, CEO & Director | 686.49k | N/A | 1955 |
Mr. Edward H. Myles MBA | CFO, COO & Treasurer | 668.49k | N/A | 1972 |
Ms. Junlin Ho J.D. | General Counsel & Corporate Secretary | 563.73k | N/A | 1979 |
Mr. Mo Qatanani Ph.D. | Chief Scientific Officer | N/A | N/A | 1974 |
Rushmie Nofsinger | Vice President of Corporate Affairs & Investor Relations | N/A | N/A | N/A |
Ms. Caryn Parlavecchio | Chief Human Resources Officer | N/A | N/A | 1972 |
Ms. Lisa Amaya Price | Senior Vice President of Human Resources | N/A | N/A | N/A |
Ms. Erin Moore | Senior Vice President of Finance | N/A | N/A | 1975 |
Mr. Ryan Iarrobino | Senior Vice President of Clinical Development & Operations | N/A | N/A | N/A |
Dr. Jing L. Marantz M.B.A., M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1965 |
Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies. It is developing a pipeline of product candidates to deliver novel therapies to treat a range of serious diseases, including neuromuscular disorders, cardiometabolic disorders, cancer, fibrosis, and iron-restricted anemia. Scholar Rock Holding Corporation was founded in 2012 and is headquartered in Cambridge, Massachusetts.
Scholar Rock Holding Corporation’s ISS Governance QualityScore as of April 29, 2024 is 7. The pillar scores are Audit: 2; Board: 7; Shareholder Rights: 8; Compensation: 9.